Cell differentiation is a key determinant of cathelicidin LL-37/human cationic antimicrobial protein 18 expression by human colon epithelium.
Hase. Koji K; Eckmann. Lars L; Leopard. John D JD; Varki. Nissi N; Kagnoff. Martin F MF
Key Findings
- LL-37 is expressed in surface and upper crypt colon cells, not in deeper crypts or the small intestine.
- Cell differentiation, induced by sodium butyrate, markedly increases LL-37 mRNA and protein in colon epithelial cells.
- Inflammatory cytokines and most gut microbes do not significantly change LL-37 levels, with only modest up‑regulation by Salmonella or invasive E. coli.
Practical Outcomes
- Boosting butyrate production through a high‑fiber diet or butyrate supplements may modestly increase LL-37 in the colon, potentially enhancing local innate immunity. However, the effect is limited and not a substitute for other health measures; more research is needed before using it as a targeted anti‑infection strategy.
Summary
LL-37, an antimicrobial peptide, is mainly made by mature cells on the surface of the colon and goes up when those cells become more differentiated, especially after exposure to butyrate, a short‑chain fatty acid. It isn’t strongly triggered by common inflammatory signals or by most gut bacteria, though certain infections can raise it a bit.
Abstract
Antimicrobial peptides are highly conserved evolutionarily and are thought to play an important role in innate immunity at intestinal mucosal surfaces. To better understand the role of the antimicrobial peptide human cathelicidin LL-37/human cationic antimicrobial protein 18 (hCAP18) in intestinal mucosal defense, we characterized the regulated expression and production of this peptide by human intestinal epithelium. LL-37/hCAP18 is shown to be expressed within epithelial cells located at the surface and upper crypts of normal human colon. Little or no expression was seen within the deeper colon crypts or within epithelial cells of the small intestine. Paralleling its expression in more differentiated epithelial cells in vivo, LL-37/hCAP18 mRNA and protein expression was upregulated in spontaneously differentiating Caco-2 human colon epithelial cells and in HCA-7 human colon epithelial cells treated with the cell differentiation-inducing agent sodium butyrate. LL-37/hCAP18 expression by colon epithelium does not require commensal bacteria, since LL-37/hCAP18 is produced with a similar expression pattern by epithelial cells in human colon xenografts that lack a luminal microflora. LL-37/hCAP18 mRNA was not upregulated in response to tumor necrosis factor alpha, interleukin 1alpha (IL-1alpha), gamma interferon, lipopolysaccharide, or IL-6, nor did the expression patterns and levels of LL-37/hCAP18 in the epithelium of the normal and inflamed colon differ. On the other hand, infection of HCA-7 cells with Salmonella enterica serovar Dublin or enteroinvasive Escherichia coli modestly upregulated LL-37/hCAP18 mRNA expression. We conclude that differentiated human colon epithelium expresses LL-37/hCAP18 as part of its repertoire of innate defense molecules and that the distribution and regulated expression of LL-37/hCAP18 in the colon differs markedly from that of other enteric antimicrobial peptides, such as defensins.
Study Information
pubmed
2002
10.1128/iai.70.2.953-963.2002